Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene expression profiling of epothilone A-resistant cells.

Peter Atadja1, Yan Yan-Neale, Harry Towbin

  • 1Functional Genomics, Novartis Corporation, Summit, NJ 07901, USA.

Novartis Foundation Symposium
|May 7, 2002
PubMed
Summary

Researchers developed epothilone A-resistant breast cancer cells, finding unique gene expression patterns distinct from multidrug resistance (MDR). These patterns involve interferon-inducible proteins and altered cell signaling, offering new insights into drug resistance mechanisms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Note: Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets.

Biochimica et biophysica acta. Molecular basis of disease·2022
Same author

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

Journal of medicinal chemistry·2022
Same author

Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.

Clinical epigenetics·2020
Same author

Editor's Note: Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-mediated Potentiation of Bortezomib-induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells.

Clinical cancer research : an official journal of the American Association for Cancer Research·2020
Same author

Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain.

SLAS discovery : advancing life sciences R & D·2018

Area of Science:

  • * Molecular biology
  • * Cancer research
  • * Pharmacology

Background:

  • * Microtubule-stabilizing agents like epothilone A are crucial in cancer therapy.
  • * Acquired resistance to chemotherapy, including epothilone A, is a significant clinical challenge.
  • * Understanding the molecular mechanisms of drug resistance is vital for developing effective treatments.

Purpose of the Study:

  • * To investigate the molecular basis of epothilone A resistance in human breast adenocarcinoma cells (MDA 435).
  • * To characterize gene expression profiles associated with epothilone A resistance, differentiating it from known multidrug resistance (MDR) mechanisms.
  • * To identify novel genes and pathways involved in epothilone A resistance.

Main Methods:

  • * Generation of epothilone A-resistant sublines from the MDA 435 cell line.

Related Experiment Videos

  • * Phenotypic characterization of resistant cells for cross-resistance to Taxol.
  • * Utilization of cDNA microarrays to analyze gene expression profiles in resistant cells.
  • * Hierarchical clustering to identify differentially expressed genes.

    • Main Results:

    • * Epothilone A-resistant cells did not express P glycoprotein or multidrug resistance-associated protein (MRP).
    • * Gene expression analysis revealed distinct profiles for epothilone A resistance compared to Taxol-resistant MDR cells.
    • * Upregulated genes in epothilone A-resistant cells included interferon-inducible proteins, microtubule-associated GTPases, cytoskeletal proteins, and a drug-metabolizing enzyme.
    • * Downregulated genes in both epothilone A- and Taxol-resistant cells were associated with cellular growth signaling.

    Conclusions:

    • * Epothilone A resistance in MDA 435 cells is mediated by mechanisms distinct from classical P glycoprotein or MRP-dependent MDR.
    • * Interferon-inducible proteins and altered expression of cytoskeletal and signaling proteins are implicated in epothilone A resistance.
    • * The findings provide novel molecular targets and insights into overcoming epothilone A resistance in breast cancer.